Skip to main content
Fig. 2 | Clinical Epigenetics

Fig. 2

From: PDCD5 inhibits progression of renal cell carcinoma by promoting T cell immunity: with the involvement of the HDAC3/microRNA-195-5p/SGK1

Fig. 2

RCC cell proliferation is inhibited, and T cell activation is promoted by upregulated PDCD5 via HDAC3. A The expression box plot of HDAC3 in RCC samples and normal samples predicted by StarBase database. B The expression of HDAC3 in RCC and adjacent non-cancerous tissues determined by Western blot analysis (n = 58). *p < 0.05 versus the RCC tissues. C The expression of HDAC3 in RCC cell line (A498) and normal renal cell line (HK-2) normalized to GAPDH determined by Western blot analysis. *p < 0.05 versus the HK-2 cell line. D The expression of HDAC3 in A498 cells after upregulation/downregulation of PDCD5 normalized to GAPDH determined by Western blot analysis. *p < 0.05 between the two groups. E The transfection efficiency of PDCD5 and HDAC3 validated by Western blot analysis. *p < 0.05 between the two groups. F A498 cell proliferation detected by EdU assay. G IFN-γ+ T cell proportion and CD3+ T cell proliferation detected by flow cytometry. H The expression of IFN-γ released from CD3+ T cells determined by ELISA. *p < 0.05. The results were measurement data and expressed as mean ± standard deviation. The results were collected from at least 3 independent cell experiments. Data between RCC and adjacent non-cancerous tissues were analyzed by paired t test and data comparison between the other two groups was analyzed by unpaired t test

Back to article page